Literature DB >> 12076287

HIV seroconverting donors delay their return: screening test implications.

George B Schreiber1, Simone A Glynn, Glen A Satten, Fanhui Kong, David Wright, Michael P Busch, Yongling Tu, Steven H Kleinman.   

Abstract

BACKGROUND: The yield of HIV p24 antigen testing implemented in March 1996 has been lower than projected. One possible explanation is that HIV seroconverting donors delay their return because of the recent practice of risk behaviors and/or signs and symptoms associated with primary infection. STUDY DESIGN AND METHODS: From a database of 6.8-million allogeneic donations collected at five U.S. blood centers from 1991 to 1997, 49 HIV, 21 HCV, 32 HTLV, and 44 HBsAg seroconverters with at least three donations were identified. A statistical method was developed to investigate whether the time between a donor's last negative donation and their positive donation was significantly longer than expected based on their previous return history.
RESULTS: HIV seroconverters returned on average 42 percent later than expected (p < 0.01). Although not significant, HCV seroconverters donated on average 43 percent earlier than expected. HTLV and HBsAg seroconverters did not appear to change their donation pattern around the time of seroconversion. Sixty-three percent of the HIV seroconverters later acknowledged practicing a high-risk behavior.
CONCLUSIONS: HIV seroconverters delay their return around the time of seroconversion and are thus less likely to be recently infected. Unique among HIV seroconverters, this observation provides a possible explanation for the lower than expected yield of HIV p24 antigen testing and suggests that NAT may have a similar low yield.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12076287     DOI: 10.1046/j.1525-1438.2002.00084.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

1.  Incidence and Residual Risk of HIV, HBV and HCV Infections Among Blood Donors in Tehran.

Authors:  Hamid Reza Saber; Seyed Morteza Tabatabaee; Ali Abasian; Mostafa Jamali; Ebadollah SalekMoghadam; Bashir Hajibeigi; Seyed Moayed Alavian; Seyed Mohammad Mirrezaie
Journal:  Indian J Hematol Blood Transfus       Date:  2016-10-01       Impact factor: 0.900

2.  The National Heart, Lung, and Blood Institute retrovirus epidemiology donor studies (Retrovirus Epidemiology Donor Study and Retrovirus Epidemiology Donor Study-II): twenty years of research to advance blood product safety and availability.

Authors:  Steven Kleinman; Melissa R King; Michael P Busch; Edward L Murphy; Simone A Glynn
Journal:  Transfus Med Rev       Date:  2012-05-24

3.  HIV Seroconversion in blood donors from the coordinating blood bank in the State of Pará.

Authors:  Andrea Silvestre Lobão Costa; Danielle Murici Brasiliense
Journal:  Rev Bras Hematol Hemoter       Date:  2011

4.  Cross-Sectional HIV Incidence Surveillance: A Benchmarking of Approaches for Estimating the 'Mean Duration of Recent Infection'.

Authors:  Reshma Kassanjee; Daniela De Angelis; Marian Farah; Debra Hanson; Jan Phillipus Lourens Labuschagne; Oliver Laeyendecker; Stéphane Le Vu; Brian Tom; Rui Wang; Alex Welte
Journal:  Stat Commun Infect Dis       Date:  2017-03-14

5.  Seroconverting blood donors as a resource for characterising and optimising recent infection testing algorithms for incidence estimation.

Authors:  Reshma Kassanjee; Alex Welte; Thomas A McWalter; Sheila M Keating; Marion Vermeulen; Susan L Stramer; Michael P Busch
Journal:  PLoS One       Date:  2011-06-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.